Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03209050 · ClinicalTrials.gov registry record · NA
Evaluation of the Surfacer System Approach to Central Venous Access
A NA study of Venous Occlusion, sponsored by Merit Medical Systems.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03209050: Completed NA study of Venous Occlusion, sponsored by Merit Medical Systems.
NCT03209050 is a NA study of Venous Occlusion that has completed, run by Merit Medical Systems. The registered enrollment target is 30 participants, below the 221-participant average among 4 other Venous Occlusion trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03209050, a NA study of Venous Occlusion, has completed, sponsored by Merit Medical Systems.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Pre-market Investigational device exemption study evaluating the safety and efficacy of the Surfacer System to facilitate stable upper body central venous access suitable for any conventional catheter.
Primary Outcome
Safety reported as 86.7% (26/30) % of subjects with no procedural complications at discharge through 7 days follow up.
Conditions Studied
Interventions
- DEVICE Central Venous Access Placement
Study Locations (1)
Texas
- Houston Methodist Research Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2019-06-01 |
| Phase | NA |
What the finished NCT03209050 record still lists
NCT03209050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 221-participant average among 4 other Venous Occlusion trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Venous Occlusion appearing as the primary indexed condition, and to 1 intervention - of which Central Venous Access Placement is the first listed.
NCT03209050 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03209050 about?
NCT03209050 is a clinical study titled "Evaluation of the Surfacer System Approach to Central Venous Access". Pre-market Investigational device exemption study evaluating the safety and efficacy of the Surfacer System to facilitate stable upper body central venous access suitable for any conventional catheter.
What is the current status of trial NCT03209050?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-12-18. Estimated completion is 2019-06-01.
What conditions does trial NCT03209050 study?
This clinical trial studies the following conditions: Venous Occlusion.
What interventions are being tested in trial NCT03209050?
The interventions under investigation include: Central Venous Access Placement (DEVICE).
Who is sponsoring clinical trial NCT03209050?
This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03209050 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Occlusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI